- Facing pharmacy trends for the remainder of the year
- Senate passes Drug Quality and Security Act
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Rite Aid posts third consecutive quarterly profit as company expands Wellness+
RESEARCH TRIANGLE PARK, N.C. — The Food and Drug Administration has approved a treatment for psoriasis of the scalp made by a subsidiary of British drug maker GlaxoSmithKline.
Stiefel announced Friday the approval of Sorilux (calcipotriene) foam for psoriasis of the scalp in adults. The drug was already approved for psoriasis of other parts of the body in October 2010.
"Studies have shown that in at least 50% of psoriasis cases, the scalp is involved," Stiefel medicines development leader for dermatology research and development Susan Learned said. "We believe this additional indication for Sorilux foam will help meet the needs of both patients and physicians."